ArticleLipids in health and disease2025
Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) can occur in both nonlean and lean individuals. This study aimed to compare the risk of cause-specific mortality between lean and nonlean MASLD patients and investigate the impact of advanced fibrosis on mortality.
methodThis population-based cohort study included 14,740 adults from the National Health and Nutrition Examination Survey (NHANES). The NAFLD Fibrosis Score (NFS) or Fibrosis-4 score (FIB-4) was employed to identify advanced fibrosis. Cox proportional hazard models were utilized to analyze all-cause mortality, whereas competing risk models were applied to analyze cause-specific mortality.
resultsDuring a median follow-up of 7.3 (4.1–10.7) years, lean MASLD patients presented increased risks for all-cause mortality (HR = 2.50, 95% CI = 1.70–3.66) and diabetes-specific mortality (sHR = 5.00, 95% CI = 1.40–17.8) compared with nonlean MASLD patients. No significant differences were observed in cardiovascular-specific or cancer-specific mortality risk between the two groups. Stratified analyses revealed a significant interaction effect between lean MASLD and advanced fibrosis on all-cause mortality risk. Among lean MASLD patients with advanced fibrosis, the incidence rates per 1,000 person-years were 110.6 (95% CI = 58.5-185.2) for all-cause mortality, 27.7 (5.7–78.7) for cardiovascular-specific mortality, 9.2 (0.2–50.3) for cancer-specific mortality and 9.2 (0.2–50.3) for diabetes-specific mortality. An FIB-4 score > 2.67 and NFS > 0.676 could indicate an increased risk of all-cause mortality in lean MASLD patients, with no significant difference in performance.
conclusionLean MASLD patients had greater risks of all-cause and diabetes-specific mortality than nonlean MASLD patients, and regular noninvasive fibrosis evaluation is recommended for lean MASLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.